BRISTOL MYERS SQUIBB
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumor
- Interventions
- Drug: HuMax-IL8
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT02536469
- Locations
- 🇺🇸
National Cancer Institute, Bethesda, Maryland, United States
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT02534506
- Locations
- 🇯🇵
Local Institution, Kobe-shi, Hyogo, Japan
Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 140
- Registration Number
- NCT02534636
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir
Completed
- Conditions
- HIV/AIDS
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1200
- Registration Number
- NCT02532673
Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period
Completed
- Conditions
- Hepatitis C
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 249
- Registration Number
- NCT02531269
- Locations
- 🇨🇭
Local Institution, Basel, Switzerland
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT02516527
- Locations
- 🇨🇳
Local Institution, Guangzhou, Guangdong, China
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 994
- Registration Number
- NCT02504268
- Locations
- 🇺🇸
Arizona Arthritis & Rheumatology Research PLLC, Sun City, Arizona, United States
🇺🇸Rheumatology Associates Of North Alabama, P.C., Huntsville, Alabama, United States
🇺🇸CHI St. Vincent Medical Group Hot Springs, Hot Springs, Arkansas, United States
Safety Profile of Nulojix in Home Infusion Settings
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 37
- Registration Number
- NCT02500498
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 207
- Registration Number
- NCT02496078
- Locations
- 🇷🇺
Local Institution, St.petersburg, Russian Federation
PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma
Completed
- Conditions
- Melanoma
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1773
- Registration Number
- NCT02492815
- Locations
- 🇬🇧
Local Institution, Guildford, Surrey, United Kingdom
🇺🇸Outcome Sciences Inc Dba Outcome, Boston, Massachusetts, United States
🇩🇪Elbe Klinikum Buxtehude, Buxtehude, Germany
© Copyright 2025. All Rights Reserved by MedPath